The firm reported total revenues of $708,000, down from $898,000 a year ago, and OVA1 sales volume of 1,884 tests, down 22 percent from 2,418 in Q2 2017.
The revenue increase was largely driven by strong international sales of the OraQuick HIV self-test, which helped offset a decline in HCV testing product sales.
A manufacturing defect caused the control line on the affected tests to not display, which can cause test results to be misinterpreted as negative for the presence of amniotic fluid.
The company said Q2 sales increased 11 percent on a currency-neutral basis, driven by growth in both its Life Science and Clinical Diagnostics segments.
Sales were driven by the cardiac testing products acquired last year from Alere and offset a decline in rapid immunoassay sales tied to the flu season.
The deal cover's Sienna's in vitro diagnostic for the detection of the hTERT component of telomerase, a biomarker that aids in the diagnosis of bladder cancer.
ProAxsis and a US-based biotechnology company codeveloped the assay as part of an ongoing collaboration. ProAxsis has made its first commercial sale of the test.
The Atellica assay's capability to assist with antibiotic therapy decisions can help address the rising problem of antibiotic resistance, Siemens said.
A spin-out of the University of Geneva and Barcelona's Vall d’Hebron Research Institute, the company is focused on protein biomarkers for brain injury.
In addition, Qiagen has partnered with Japan's SRL for companion diagnostic development, and its CareHPV test was added to the WHO list of prequalified IVDs.
The company posted $29.3 million in revenues for the quarter, including $25 million from its tuberculosis business, which grew 17 percent year over year.
